Search Results

1-7 of 7 results for subject:Oripavine

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Defence, if he will instruct the chemical defence establishment, Porton Down, to conduct research to determine the long-term effects of a single dose of the oripavine derivative TL 2636 on the health of humans.

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Date

2 July 2001

Reference

989; 371 c3W

House

House of Commons

Deposited Paper DEP 01/834

Deposited by

Ministry of Defence

Type

Deposited papers

Date

25 May 2001

Reference

DEP 01/834

House

House of Commons

Ministry of Defence

To ask the Secretary of State for Defence, pursuant to his Answer of 25th January, Official Report, 361 c659W, on oripavine, if he will place in the Library details of the evidence which suggests that following single acute doses of TL2636 there are no significant long-term effects on health. -...

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Date

8 May 2001

Reference

368 c23W;368 c15W; 159805

House

House of Commons

Ministry of Defence

To ask the Secretary of State for Defence, pursuant to his Answer of 5th March, Official Report, 364 c20W, on Porton Down, if he will place in the Library copies of each of the internal technical reports related to research involving oripavine TL 2636 identified by the Chemical and Biological...

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Date

8 May 2001

Reference

368 c15W; 159802

House

House of Commons

Ministry of Defence

To ask the Secretary of State for Defence, what plans the Chemical Defence Establishment, Porton Down, has to conduct research to establish whether single doses of the oripavine derivative TL 2636 can cause long-term effects on the health of humans.

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Date

3 May 2001

Reference

367 c716W; 159801

House

House of Commons

Ministry of Defence

To ask the Secretary of State for Defence, pursant to his Answer of 25th January 2001 at 361 c659W, regarding oripavine, if he will place in the Libary a list of the technical papers which discuss the different aspects of Porton's research on TL 2636, specifying the title, number and...

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Tabled on

27 February 2001

For answer on

5 March 2001

Answered on

5 March 2001

Mr. Matthew Taylor: To ask the Secretary of State for Defence pursuant to his answer of 25 January 2001, Official Report, column 659W, regarding Oripavine, if he will place in the Library a list of the technical papers which discuss the different aspects of Porton's research on TL2636, specifying the title, number and date of each paper. [152050] Dr. Moonie: The Chemical and Biological Defence Sector of DERA at Porton Down have identified several internal technical reports which relate to research involving Oripavine TL2636. These are as follows: Porton Technical Paper 0835: Oripavine derivative (TL2636) as a potential incapacitating agent. 1963 Porton Technical Paper 0951: Prediction of biological activity. 1966 Nancekuke Internal Note 9: Some applications of potentiometric titrations in non-aqueous media. 1965 Nancekuke Internal Note 16: Analysis of tertiary alcohols of the 6:14 endetheno tetrahydro Oripavine series. 1966 Nancekuke Report 78: Preparation of tertiary alcohols of the 6:14 endetheno tetrahydro Oripavine series. 1966 Porton Down Technical Paper 939: N-dealkylation of Oripavine derivatives and its significance in their pharmacological activity. Date unknown. Technical Paper 008: Neuropharmacological comparison in the cat of the catalepsy producing drugs morphine and bulbocapnine. 1969 Technical Paper 068: Effects of small doses of an Oripavine derivative on human subjects under both laboratory and field conditions. 1972. The following three reports have some reference to Oripavine TL2636: Annual Summary Report 1965-1966. 1966 CW Applications Discussion Group: 17{th} Quadripartite CBR Conference. 1964 Applied Biology Committee Chemical Defence Establishment: Effects of small doses of TL2636 on human subjects at rest and exercising in the laboratory and the field. 1968. The majority of these reports are over 30-years-old and are part of the Porton Down archive holding of records which have been progressively transferred to the main MOD repository at Hayes. Since 1998, the majority of the above technical reports and other material have been forwarded to MOD archives for review, in accordance with normal procedures, and eventual transfer to the Public Records Office.

Date

5 March 2001

Reference

152050; 364 c20W

House

House of Commons

Ministry of Defence

To ask the Secretary of State for Defence, how many service volunteers were tested with the oripavine derivative TL 2636 by staff of the chemical defence establishment, Porton Down, and in what years; for what reasons the tests were (a) started and (b) ended; what the results of these tests...

Asked by

Lord Taylor of Goss Moor (Liberal Democrat)

Answering body

Ministry of Defence

Type

Written questions

Status

Answered

Tabled on

17 January 2001

For answer on

25 January 2001

Answered on

25 January 2001

Mr. Matthew Taylor: To ask the Secretary of State for Defence how many service volunteers were tested with the oripavine derivative TL 2636 by staff of the chemical defence establishment, Porton Down, and in what years; for what reasons the tests were (a) started and (b) ended; what the results of these tests were; how many technical papers recording the results of these tests have been produced by Porton Down staff; and what research has been carried out by his Department to establish the long-term effects of this chemical on the health of individuals. [146687] Dr. Moonie: The Service Volunteer Programme at the Chemical and Biological Defence Sector of DERA at Porton Down has undertaken research with the oripavine derivative TL 2636 as an incapacitating agent, part of which has involved service volunteers. The results of this aspect of research are collated in two formal technical papers, one of which covers the period between August 1961 and November 1963 and the second which details a particular trial in January 1968. However, there are several other technical papers which discuss different aspects of the research programme pertaining to this compound. The volunteer studies were undertaken because there was concern that this or similar compounds may be deployed against the UK armed forces to cause temporary incapacitation. A total of 141 service volunteers were involved in these studies which concluded that oripavine had the potential to cause both physical and mental incapacitation. To date no long-term follow-up studies have been undertaken, however TL 2636 is a member of the same group of drugs as morphine which has been used clinically for many years. The current evidence suggests that following single, acute doses of such compounds there are no significant long-term effects on health.

Date

25 January 2001

Reference

146687; 361 c659W;361 c657-8W

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher